Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2022-05-23 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
北京德恒（深圳）律师事务所关于深圳市海王生物股份有限公司2021年年度股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the 2021 Annual General Meeting (AGM) of Shenzhen Haiwang Bioengineering Co., Ltd. It details the legality of the meeting's convening, attendance, voting procedures, and results. The document references the 2021 AGM specifically and focuses on the legal validation of the meeting and its resolutions. It does not contain financial statements or detailed financial performance data, nor is it a transcript or presentation. It is not an announcement of the AGM but a legal opinion related to the AGM. Therefore, the document fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on the official voting results and validates the meeting's legality.
2022-05-23 Chinese
2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2021 Annual General Meeting (AGM) of Shenzhen Haiwang Bioengineering Co., Ltd. It includes voting results on various proposals such as the 2021 Board Work Report, Supervisory Board Work Report, Financial Statements, Profit Distribution Plan, Annual Report, Auditor Reappointment, and Related Party Transactions. The document also confirms the legality and validity of the meeting and voting process, supported by a legal opinion from a law firm. The content focuses on the official voting results and meeting details rather than the full annual report or financial statements themselves. The document length is 4364 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-05-23 Chinese
关于为控股子公司提供担保实施情况的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the provision of guarantees for its controlling subsidiaries. It lists multiple guarantee contracts with banks and financial institutions, specifying amounts, terms, and conditions. The document is an announcement about the company's guarantee activities rather than a financial report or audit. It does not contain financial statements or earnings data, nor is it a transcript or presentation. It is a regulatory announcement about guarantees provided, which fits best under the category of Regulatory Filings (RNS) as it is a compliance disclosure about guarantees and related contractual details.
2022-05-13 Chinese
独立董事对担保等事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' special statement and independent opinions regarding various company matters related to the 8th Board of Directors' 27th meeting. It covers topics such as external guarantees, profit distribution proposals, asset impairment provisions, internal control self-evaluation report, reappointment of the audit firm, and daily related party transactions for 2021 and 2022. The document is a formal opinion and explanation by independent directors on board meeting matters, not a full annual report or audit report. It is not a financial statement or earnings release but a governance-related disclosure tied to board decisions and compliance with regulatory guidelines. Therefore, it fits best under Board/Management Information (MANG) as it relates to board meeting matters and independent directors' opinions on company governance and financial matters discussed at the board level.
2022-04-28 Chinese
监事会决议公告
Audit Report / Information Classification · 95% confidence The document is a supervisory board's review and opinion on several company reports and proposals, including the 2021 annual report, 2022 first quarter report, profit distribution plan, asset impairment provisions, and internal control self-evaluation report. It does not contain the actual financial statements or detailed financial data but rather opinions and confirmations on the reports prepared by the board. The document length is short (1194 characters), and it serves as an audit or supervisory opinion on various reports rather than the reports themselves. This fits best under Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, excluding full annual or quarterly reports. FY 2021
2022-04-28 Chinese
关于2021年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2021 annual profit distribution plan of Shenzhen Haier Bioengineering Co., Ltd. It details the decision not to distribute dividends or convert capital reserves into shares for the year 2021. The document includes opinions from the board of supervisors and independent directors and states that the plan will be submitted to the shareholders' meeting for approval. The document is relatively short (1568 characters) and serves as a formal announcement of a profit distribution plan rather than a full financial report or detailed annual report. It does not contain comprehensive financial statements or detailed analysis but focuses on the dividend distribution decision and related approvals. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and related shareholder information.
2022-04-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.